CHAD CREIGHTON to TOR Serine-Threonine Kinases
This is a "connection" page, showing publications CHAD CREIGHTON has written about TOR Serine-Threonine Kinases.
Connection Strength
1.236
-
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell. 2017 06 12; 31(6):820-832.e3.
Score: 0.442
-
MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling. J Clin Invest. 2019 03 01; 129(3):1015-1029.
Score: 0.124
-
Multiplatform-based molecular subtypes of non-small-cell lung cancer. Oncogene. 2017 03; 36(10):1384-1393.
Score: 0.106
-
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep. 2016 Mar 15; 14(10):2476-89.
Score: 0.102
-
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014 Mar 20; 507(7492):315-22.
Score: 0.088
-
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat. 2013 Apr; 138(2):369-81.
Score: 0.082
-
Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res. 2012 Sep 01; 18(17):4633-45.
Score: 0.079
-
Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.
Score: 0.059
-
A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene. 2007 Jul 12; 26(32):4648-55.
Score: 0.054
-
MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade. Nat Commun. 2022 01 11; 13(1):245.
Score: 0.038
-
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014 Dec; 46(12):1267-73.
Score: 0.023
-
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
Score: 0.023
-
A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol. 2010 Feb; 24(2):447-63.
Score: 0.017